TRUMENBA safety information
Scroll for Important Safety Information and Indication
IMPORTANT SAFETY INFORMATION
- Severe allergic reaction after a previous dose of Trumenba is a contraindication
- Individuals with altered immunocompetence may have reduced immune responses to Trumenba
- In clinical studies, the most common solicited adverse reactions were pain at the injection site (≥85%), fatigue (≥40%), headache (≥35%), muscle pain (≥30%), and chills (≥15%)
- Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
- Safety and effectiveness has not been established in pregnant women
- Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
- Approval of Trumenba is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the United States. The effectiveness of Trumenba against diverse serogroup B strains has not been confirmed
Please see full Prescribing Information.
TRUMENBA in your practice
The science behind TRUMENBA
TRUMENBA clinical studies
*Advisory Committee on Immunization Practices.
- Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2016.
- MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1177.